SYRS vs. NCNA, NAVB, SMFL, VRPX, SCPS, VAXX, EVLO, CMRA, GNCAQ, and GNCA
Should you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include NuCana (NCNA), Navidea Biopharmaceuticals (NAVB), Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), and Genocea Biosciences (GNCA). These companies are all part of the "pharmaceutical products" industry.
Syros Pharmaceuticals vs. Its Competitors
Syros Pharmaceuticals (NASDAQ:SYRS) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.
91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Syros Pharmaceuticals presently has a consensus target price of $1.00, suggesting a potential upside of 4,925.13%. NuCana has a consensus target price of $5,000.00, suggesting a potential upside of 145,248.84%. Given NuCana's stronger consensus rating and higher probable upside, analysts plainly believe NuCana is more favorable than Syros Pharmaceuticals.
Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, NuCana has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
In the previous week, NuCana had 4 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 4 mentions for NuCana and 0 mentions for Syros Pharmaceuticals. NuCana's average media sentiment score of 0.75 beat Syros Pharmaceuticals' score of 0.00 indicating that NuCana is being referred to more favorably in the news media.
NuCana has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.
NuCana's return on equity of -592.28% beat Syros Pharmaceuticals' return on equity.
Summary
NuCana beats Syros Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
Get Syros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syros Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SYRS) was last updated on 8/23/2025 by MarketBeat.com Staff
MarketBeat All Access